Adrenal Tumors/Cancer

U-M startup company secures license, funding to test potential drugs aimed at endocrine disorders

Millendo Therapeutics, a University of Michigan startup company, announced today that it has entered into an exclusive license agreement with AstraZeneca for the worldwide development and commercialization rights to test a new compound, MLE4901, for the treatment of polycystic ovary syndrome.

Read more about U-M startup company secures license, funding to test potential drugs aimed at endocrine disorders

Hovnanian Foundation gives U-M $1.65M for adrenal cancer research

The University of Michigan Rogel Cancer Center received a $1.65 million gift from the Hirair and Anna Hovnanian Foundation to fund adrenal cancer research.

Read more about Hovnanian Foundation gives U-M $1.65M for adrenal cancer research

Study suggests precision medicine for adrenal cancer

In a randomized phase 3 trial, adrenal cancer patients receiving the investigational drug linsitinib fared no better than patients receiving a placebo. But the researchers noticed a small subset of patients who had significant response and remained on the drug for an extended time.